Blockchain Registration Transaction Record

TransCode Therapeutics Initiates Phase 2a Trial for TTX-MC138 in Colorectal Cancer

TransCode Therapeutics announces Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, targeting microRNA-10b to reduce recurrence risk.

This news matters because it addresses a critical unmet need in oncology: patients with minimal residual disease (ctDNA-positive but no radiographic evidence) are at high risk of recurrence and have few options. If successful, TTX-MC138 could become a first-in-class therapy to prevent metastasis, potentially changing treatment paradigms for colorectal and other cancers. The use of the PRE-I-SPY platform also highlights a shift toward more efficient clinical trial designs that could bring life-saving drugs to patients faster.